A Phase 2 Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
Latest Information Update: 13 May 2024
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Biliary cancer; Bladder cancer; Colorectal cancer; Endometrial cancer; Lung cancer; Ovarian cancer; Salivary gland cancer; Solid tumours; Urogenital cancer
- Focus Therapeutic Use
- 07 May 2024 Planned End Date changed from 1 Feb 2024 to 1 Feb 2025.
- 07 May 2024 Planned primary completion date changed from 1 Feb 2024 to 1 Feb 2025.
- 06 Jun 2023 Primary endpoint has not been met (Overall response rate (ORR) in patients with HER2 mutant - in patients with HER2 amplified endometrial, colorectal and other cancers) , according to Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology